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Epilepsy, one of the most common neurological disorders, is a  chronic disease of the brain manifested by seizures due to 
sudden, spontaneous bioelectrical discharges in nerve cells. An estimated 50 million people worldwide suffer from epilepsy. 
Antiepileptic drugs are the mainstream treatment for epilepsy; however, the drug resistance occurring in 20‑30% of patients 
and side effects of available medications have resulted in a  search for natural remedies that can support disease therapy. 
Coumarins may be a  promising option. They are a  group of natural plant‑derived substances of great interest due to their 
broad spectrum of biological activities, including potent pharmacological properties. Recent data from experimental models 
demonstrates the possibility for coumarin use as a supporting treatment of epileptic seizures. This article focuses on the most 
recent research reports available in the literature relating to the use of several selected coumarins in different experimental 
models of epilepsy.
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INTRODUCTION
Coumarins are organic, biologically active com‑
pounds belonging to the benzopyrone family (1,2‑ben‑
zopyrones or 2H‑1‑benzopyran‑2‑ones). They are di‑
vided into four subtypes based on their chemical struc‑
ture. Simple coumarins are formed by benzene rings 
fused with α‑pirons which are hydroxylated, alkoxyl‑
ated or alkylated at the C7, C6 and C3 positions of ben‑
zopyrone. Isocoumarin derivatives are formed by two 
rings: benzene and α‑isopirone with substituents in po‑
sitions C3, C6, C7 and C8. Furanocoumarins, consisting 
of a five‑membered furan ring fused with coumarin, are 
divided into two types – psoralen, at the C6‑C7 posi‑
tions, or angelicin, at the C7‑C8 position. Pyranocou‑
marins, with substituents, condense a six‑membered 
pyran ring with a coumarin ring at the C6‑C7 position 
(Mead et al., 1958; Jain et al., 2012; Medina et al., 2015). 
Variable chemical structures and a diversity of substi‑
tutions in the skeleton affect the diverse pharmacolog‑
ical activities of coumarins (Kumar et al., 2015; Kubrak 
et al., 2017). Coumarins are mainly found in secondary 
plant metabolites, acting as growth regulators, con‑
trolling biochemical transformations and demonstrat‑
ing defensive properties against infection (Chattha et 
al., 2018). They are also found in some bacteria, fungi 
or sponges and can be synthesized chemically (Matos 
et al., 2015).
Coumarins and coumarin‑related compounds pos‑
sess a wide range of pharmacological profiles. Their 
properties and their impact on the cardiovascular sys‑
tem (Najmanova et al., 2015), nervous system (Skalic‑
ka‑Woźniak et al., 2016), body immunity (Rohini et al., 
2014) and digestive system (Popp et al., 2017) are cur‑
rently being researched. New derivatives are still being 
discovered and synthesized due to their potential uses.
Recent studies have revealed the effective use of 
coumarins in cancer therapy as medicaments and for 
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mitigating the effects of radiotherapy (Rohini et al., 
2014). One of the most common coumarins, warfarin 
(4‑hydroxycoumarin), is used in medicine as an oral 
anticoagulant (Kumar et al., 2015). Antitumor activi‑
ty has been demonstrated for osthole in the suppres‑
sion of the spread of breast cancer cells. Tests with 
bioluminescence have shown that osthole inhibits the 
promoter of matrix metalloproteinase‑2 (MMP‑2) and 
indirectly inhibits the activity of this enzyme, which 
may lead to inhibition of tumor migration (Yang et 
al., 2010). Anticancer properties were also exhibited 
by imperatorin, esculetin, chartreusin and fraxetin 
with various mechanisms of action (Luo et al., 2011). 
Interestingly, coumarins have been shown to possess 
strong anti‑inflammatory properties. This is due to 
their antioxidant activity and effect on reactive ox‑
ygen species. Esculetin exhibited protective effects 
on rat intestines in colitis (Witaicenis et al., 2010). 
In other studies, extracts used externally have been 
shown to reduce skin inflammation and edema (Kwon 
et al., 2011). Derivatives such as esculetin, fraxetin 
and daphnetin exhibit antioxidant activity, acting as 
inhibitors of the lipoxygenase and cyclooxygenase 
enzyme pathways (Kirsch et al., 2016). In vitro studies 
on coumarin compounds have served to demonstrate 
their antimicrobial and antifungal activity. Tests car‑
ried out on Staphylococcus aureus, Bacillus subtilis and 
Escherichia coli strains revealed a much stronger an‑
tibacterial effect of synthetic coumarin compounds 
compared to several conventional antibiotics (Vyas 
et al., 2012). Much research has been devoted to the 
effect of coumarins on the central nervous system 
(CNS). Therefore, numerous experimental studies fo‑
cus on disorders such as epilepsy, schizophrenia, de‑
pressive and anxiety disorders or Alzheimer’s disease 
(Skalicka‑Woźniak et al., 2016).
Possible anticonvulsant properties  
of natural coumarins
Epileptic seizures are the result of excessive abnor‑
mal neuronal activity in the brain. The primary treat‑
ment for epilepsy is the administration of antiepileptic 
drugs (AEDs). These drugs reduce the frequency of sei‑
zures and help patients control seizure occurrence. Un‑
fortunately, a significant proportion of patients exhibit 
little or no improvement with current drug therapies. 
Moreover, the issue of chronic side effects due to the 
drugs is also significant (Sharma et al., 2013).
Experimental epileptic models are used to assess 
the activity of potential anticonvulsant drugs and 
enable an estimation of the clinical profile of a sub‑
stance’s action on the CNS. One of the basic in vivo 
animal models for assessing potential anticonvulsant 
properties of drugs is the maximal electroshock sei‑
zure (MES) test in rodents (Castel‑Branco et al., 2009). 
It allows for the modeling of specific pharmacodynam‑
ic effects required to protect against seizures. Addi‑
tionally, it is possible to assess the bioavailability of 
a given substance based on the analysis of its concen‑
tration in specific brain structures in post‑mortem tis‑
sue preparations (Rogawski et al., 2006).
Anticonvulsant effects of coumarins are likely re‑
lated to their influence on the ionotropic receptor for 
γ‑aminobutyric acid (GABA). This was demonstrated 
by studies in which furanocoumarins were found to be 
partial benzodiazepine receptor antagonists, inhibiting 
the binding [3H] of diazepam to these receptors (Sing‑
huber et al., 2011). In this study, which examined the 
effects of eighteen furanocoumarins on GABA‑induced 
chloride currents (IGABA), seven compounds showed 
a greater than 20% enhancement of IGABA. Similar re‑
sults were obtained in studies of coumarins isolated 
from Angelica pubescens (L.) that described their GAB‑
AA receptor‑modulating activity (Zaugg et al., 2011). In 
vivo analysis of the anticonvulsive activity of couma‑
rins suggests they may indirectly act to increase GABA 
concentration in the CNS by affecting the activity of 
glutamic acid decarboxylase (Luszczki et al., 2007a; Sin‑
ghuber et al., 2011; Zaugg et al., 2011).
Recent research provides evidence of positive sup‑
porting effects for coumarin compounds on the con‑
ventional AEDs (Table I, Table II). The promising phar‑
macological activity was demonstrated by the simple 
coumarins osthole and umbelliferone and also by sev‑
eral furanocoumarins – xanthotoxin and imperatorin 
(Luszczki et al., 2007a; 2009; 2010; 2011).
Osthole
Osthole (7‑methoxy‑8‑(3‑methyl‑2‑butenyl)‑2H‑1‑
‑benzopyran‑2‑one) is a simple natural origin coumarin, 
which occurs in several medicinal plants such as Cnidium 
monnieri (L.) or Angelica pubescens (L.). Both in vitro and 
in vivo studies have revealed that osthole demonstrates 
neuroprotective (Liu et al., 2010), osteogenic (Ming et 
al., 2011), immunomodulatory (Liao et al., 2010), anti‑
cancer (Yang et al., 2010; Kao et al., 2012), hepatoprotec‑
tive (Zhang et al., 2011), anticoagulant and antimicrobial 
properties (Rosselli et al., 2007).
The neuroprotective effects of osthole are related 
to an increase in neuronal conduction in the hippo‑
campus. Osthole affects the membrane receptors by 
increasing the release of glutamate from rat hippo‑
campal nerve terminals. It facilitated 4‑aminopyridine 
(4‑AP‑)‑evoked glutamate release by activating N‑ and 
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P/Q‑type Ca2+ channels through a signaling cascade in‑
volving protein kinase C (Wang et al., 2008). 
In addition to the above‑mentioned mechanism, and 
based on the intensification of glutamatergic transmis‑
sion, the anticonvulsant activity of osthole has also 
been associated with modulation of membrane channel 
activity via blocking L‑type Ca2+ channels and Na+ chan‑
nels in mouse neuronal cells (Wu et al., 2002; Leung et 
al., 2010). Osthole was found to inhibit voltage‑gated 
Na+ currents dependent upon its intracellular concen‑
tration and the current functional potential of the cell 
membrane in an N2A mouse neuroblastoma cell line 
(Leung et al., 2010). Moreover, osthole was identified as 
an activator of the GABAA receptor in vitro (Zaugg et al., 
2011; Singhuber et al., 2011). 
Research conducted by Luszczki et al. (2009) showed 
that osthole reduced seizures induced by the MES test 
in mice. The experiment was performed by a system‑
atic administration of the compound 15, 30, 60 and 
120 minutes before the test. The maximal anticonvul‑
sant effect was obtained after intraperitoneal (i.p.) ad‑
ministration of osthole between 15 and 30 minutes. In 
addition, chimney test results showed no disturbances 
in motor coordination.
Subsequent studies conducted by Luszczki et al. 
(2010) for various combinations of osthole with classic 
AEDs showed that osthole at a dose of 200 mg/kg sig‑
nificantly increased the electroconvulsive threshold in 
mice. Osthole administered with carbamazepine (CBZ), 
phenobarbital (PB), phenytoin (PHT) and valproate 
(VPA) did not have a significant effect on the anticon‑
vulsant activity of the studied drugs (at test doses for 
osthole 50, 100 and 150 mg/kg). Assessment of the mo‑
tor performance of the mice treated with the combina‑
tions of osthole and the above‑mentioned classical AEDs 
showed no side effects (Luszczki et al., 2010; 2011).
Umbelliferone
Umbelliferone (7‑hydroxycoumarin) is a commonly 
occurring coumarin plant widely occurring in the Apia-
ceae (Umbelliferae) and Rutaceae families. Umbelliferone 
exhibits various pharmacological activities including 
antihyperglycemic (Ramesh et al., 2006), bronchodi‑
lating (Vasconcelos et al., 2009), antiedematogenic 
(Toyama et al., 2009), neuroprotective (Subramaniam 
et al., 2013), antinociceptive (Barros et al., 2010) and 
anticonvulsant (Zagaja, et al., 2015a) properties. Due to 
its simple structure, it is used as a parent compound 
in the synthesis of various coumarins and heterocyclic 
compounds (Mazimba et al., 2017).
Subramaniam and Ellis (2013) identified a neuro‑
protective effect for umbelliferone, where this couma‑
Table I. Effect of coumarins on the anticonvulsant activity of conventional antiepileptic drugs against maximal electroshock‑induced seizures in mice.
CBZ
ED50 (mg/kg)
PB
ED50 (mg/kg)
PHT
ED50 (mg/kg)
VPA
ED50 (mg/kg)
References
Imperatorin + AEDs 10.36.0
19.6
12.2
12.8
8.5
247.9
213.4 Luszczki et al., 2007
Osthole + AEDs 8.876.89
18.17
12.35
9.2
7.48
212.5
173.8 Luszczki et al., 2010; 2011
Umbelliferon + AEDs 13.9711.76
35.39
21.78
13.26
10.84
281.4
215.5 Zagaja et al., 2015a
Xanthotoxin + AEDs 13.975.01
35.39
27.87
13.26
12.21
281.4
195.5 Zagaja et al., 2015b
Results are presented as median effective doses (ED50 in  mg/kg; with 95% confidence limits in parentheses) required to protect 50% of animals tested against maximal 
electroshock‑induced seizures. Bolded ED50 values corresponds to the significantly reduced effective dose of combination in comparison to the AED itself. AEDs – antiepileptic 
drugs, CBZ – carbamazepine, PB – phenobarbital, PHT – phenytoin, VPA – valproate.
Table II. Effect of imperatorin and xanthotoxin on the protective activity of various novel antiepileptic drugs against maximal electroshock‑induced seizures 
in mice.
LCM
ED50 (mg/kg)
LTG
ED50 (mg/kg)
OXC
ED50 (mg/kg)
PGB
ED50 (mg/kg)
TPM
ED50 (mg/kg)
References
Imperatorin + AEDs – 6.11 2.47 – – – Luszczki et al., 2008
Xanthotoxin + AEDs 8.70 3.96 
5.96 
5.01 
12.49 
7.54 
77.37 
28.26 
68.81 
28.84 Zagaja et al., 2016
Results are presented as median effective doses (ED50 in  mg/kg; with 95% confidence limits in parentheses) required to protect 50% of animals tested against maximal 
electroshock‑induced seizures. Bolded ED50 values corresponds to the significantly reduced effective dose of combination in comparison to the AED itself. AEDs – antiepileptic 
drugs, LCM – lacosamide, LTG – lamotrigine, OXC – oxcarbazepine, PGB – pregabalin, TPM – topiramate.
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rin significantly attenuated MPTP‑induced neurotoxic‑
ity at the cellular level in mice by preventing the loss 
of dopaminergic neurons in the substantia nigra pars 
compacta. 
Zagaja et al. (2015a) examined the antiepileptic ac‑
tivity of umbelliferone alone and in combination ther‑
apy with classical AEDs in the MES model in mice. Um‑
belliferone was administered (i.p) at doses of 50, 100 
and 150 mg/kg 30 minutes before electroshock. Umbel‑
liferone alone at a dose of 150 mg/kg significantly in‑
creased the threshold for the maximal electroshock‑in‑
duced seizure test CS50 in mice (about 37%). Interesting‑
ly, the same dose of umbelliferone enhanced the anti‑
convulsant effect of VPA and PB, reducing the ED50 from 
281.4 to 215.5 mg/kg for VPA and 35.39 to 21.78 mg/kg 
for PB. Results from the total VPA and PB brain con‑
centrations showed that the interaction between um‑
belliferone and AEDs was pharmacodynamic in nature. 
Moreover, no side effects such as impaired motor coor‑
dination, muscle strength or long‑term memory were 
observed in the mice.
Xanthotoxin
Xanthotoxin, known as methoxsalen (8‑methoxy‑
psoralen), is furanocoumarin commonly occurring in 
plants. A high content was found in the Apiaceae family 
plant Ammi majus (L.), possessing numerous pharmacolog‑
ically active properties, including photoreactivity used to 
treat skin autoimmune diseases (Selim et al., 2012).
It has been shown that xanthotoxin effectively pen‑
etrates the blood‑brain barrier (BBB) (Tian et al., 2015). 
Skalicka‑Wozniak and coworkers (2018) indicated that 
xanthotoxin improved the ability to remember in mice 
with scopolamine‑induced memory deficits. Addition‑
ally, another study by Skalicka‑Wozniak et al. (2014) 
showed an anticonvulsant effect for xanthotoxin in the 
mouse MES model. The compound had the most effec‑
tive protective effect (ED50=219.1 ± 4.7 mg/kg) when ad‑
ministered 60 minutes before the test. 
Zagaja et al. (2015b) studied the effect of xanthotox‑
in on classic AEDs. The compound was administered in 
doses of 50, 100 and 150 mg/kg and protective activity 
was based on the evaluated threshold for MES. Xan‑
thotoxin (100 mg/kg, i.p.) in combination with carba‑
mazepine (CBZ) and VPA significantly increased their 
anticonvulsant activity (p<0.001): CBZ by 64% and VPA 
by 31%. Pharmacokinetics were assessed based on drug 
concentration in the post‑mortem study of brain tissue. 
It was established that xanthotoxin increased the total 
concentration of CBZ and VPA in brain by 84% and 46%, 
respectively, compared to CBZ and VPA alone mice.
Similar research was carried out by the same team 
to assess the effect of xanthotoxin on the new‑gener‑
ation drugs lacosamide (LCM), pregabalin (PGB), topi‑
ramate (TP), oxcarbazepine (OXC) and lamotrigine 
(LTG) (Zagaja et al., 2016). As in the previous study, the 
protective activity of the drugs was determined based 
on the median effective doses (ED50 values in mg/kg) 
correlated to the maximum convulsions caused by 
electroconvulsion. Increased anticonvulsant effect was 
demonstrated for the combination of LCM, PGB, TP and 
OXC with xanthotoxin (100 mg/kg, i.p.). The assess‑
ment of long‑term memory in the passive avoidance 
test showed no side effects in mice. The chimney test 
showed no significant changes in the motor coordina‑
tion of mice. Only PGB caused a significant (75%) move‑
ment disturbance in comparison to the control group. 
Administration of xanthotoxin did not affect the total 
concentration of the drugs studied in the brain.
Imperatorin
Imperatorin (9‑[(3‑methyl‑2‑buten‑1‑yl)oxy]‑7H‑fu‑
ro[3,2‑g]chromen‑7‑one), a furanocoumarin, is pro‑
duced as a secondary metabolite of plants from the 
Apiaceae and Rutaceae families. It possesses numerous 
pharmacological activities and, among other things, ex‑
erts a significant impact on the CNS (Kozioł et al., 2016).
Imperatorin affects the CNS through various mech‑
anisms. It has been shown to act by inhibiting GABA 
transaminase and increasing the concentration of syn‑
aptic GABA in neurons—suggesting a similar activity to 
vigabatrin (Choi et al., 2005). In studies by Zaugg et al. 
(2011), imperatorin, like osthole, is modulator of the 
GABAA receptor. Moreover, imperatorin inhibits volt‑
Fig. 1. Chemical structures of coumarins:  
A. Osthole, B. Umbelliferone, C. Xanthotoxin, D. Imperatorin.
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age‑gated Na+ channel (VGSC) activity and suppresses 
action potential amplitude (Wu et al., 2013). In addi‑
tion, imperatorin was shown to desensitize transient 
reversal potential (TRP) V1 channels, and such action 
may account for the anti‑nociceptive effects of imper‑
atorin on formalin‑ and capsaicin‑induced pain in rats 
(Chen et al., 2014). Furthermore, Wang et al. (2015) 
suggest that imperatorin inhibited both Kv and KATP 
channels.
It has also been shown that imperatorin inhibits 
acetylcholinesterase activity in thin‑layer chromatog‑
raphy (TLC) bioautography (Urbain et al., 2005). Inter‑
estingly, results presented by Cao and colleagues (2017) 
were indicative of antidepressant properties for imper‑
atorin. Long‑term oral administration of imperatorin 
at 15 and 30 mg/kg/day for 28 days increased the 5‑HT 
concentration in rat hippocampus.
Imperatorin anticonvulsant activity was demonstrat‑
ed in preclinical studies by Luszczki et al. (2007a) in the 
mouse MES threshold model. In this study, imperatorin 
increased the convulsive threshold in a dose‑dependent 
manner. Statistically significant results were obtained 
for doses of 50 and 100 mg/kg administered (i.p.) at 30, 
60 and 120 minutes prior to the test. 
The influence of imperatorin on the antiepilep‑
tic action of the four classic AEDs was demonstrated 
in a study by Luszczki et al. (2007b). The anticonvul‑
sant activity of CBZ, PB, PHT and VPA was studied in 
combination with several doses of imperatorin (20, 30, 
40 mg/kg) in the MES test. A significant reduction of 
ED50 and an increase in the effect of the drugs were ob‑
served for PHT, PB and CBZ with 40 mg/kg of impera‑
torin (by 34, 38 and 42%, respectively). Statistically sig‑
nificant effects were also achieved for the combination 
of CBZ with imperatorin at a dose of 30 mg/kg (low‑
ered ED50 by 32%). Combinations of imperatorin with 
the drugs did not disturb the muscular strength of ani‑
mals in the grip‑strength test or long‑term memory in 
the passive avoidance test. Analysis of the total brain 
concentration of the AEDs showed no effect of imper‑
atorin (at a dose of 40 mg/kg) on the total concentra‑
tion of PHT and PB, which proves that the observed in‑
teractions were pharmacodynamic in nature. In turn, 
the concentration of CBZ, which was significantly in‑
creased in comparison to control, indicated a pharma‑
cokinetic nature of the imperatorin and CBZ interac‑
tion. Similarly, imperatorin at a dose of 50 mg/kg was 
shown to reduce the median effective dose of LTG from 
6.11 to 2.47 mg/kg in mouse MES model (Luszczki et 
al., 2008). Moreover, imperatorin had no impact on the 
acute adverse effects of lamotrigine in the chimney test 
and results from total brain LTG concentration analysis 
did not indicate any pharmacokinetic interaction be‑
tween drugs (Table II).
CONCLUSIONS
Looking for new anti‑epileptic drugs is a long‑term 
process requiring thorough research. Phytochemicals, 
commonly found in plants, are characterized by in‑
teresting bioactive properties, including pharmaco‑
logical ones. Among these substances, coumarins and 
their derivatives demonstrate beneficial, significant 
anticonvulsant activity. Coumarins have similarly 
been shown to act as anticonvulsants in various in vi-
tro and in vivo assays, yielding promising results at the 
preclinical stage of experimental models of epilepsy. 
There are currently observable trends of supporting 
anti‑epileptic treatment, especially drug‑resistant 
epilepsy, with various “natural” diets. Therefore, pa‑
tients treated with classic antiepileptic drugs may 
use “healthy” supplements prepared from medicinal 
plants and herbs, including coumarins, which may af‑
fect the anticonvulsant effect of antiepileptic drugs. 
In searching for novel medications, it is necessary to 
remember that the most important guideline is pa‑
tient safety. Therefore, further evaluation of couma‑
rins and approximations of the mechanism of their 
action is needed so that in the future they can support 
therapies for epileptic patients.
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